Technical Analysis for AMRN - Amarin Corporation plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
6.59 | -5.72% | -0.40 |
AMRN closed down 5.72 percent on Tuesday, August 11, 2020, on 1.12 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: Aug 19
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical AMRN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -5.72% | |
| Upper Bollinger Band Walk | Strength | -5.72% | |
| Upper Bollinger Band Touch | Strength | -5.72% | |
| Shooting Star Candlestick | Bearish | -5.86% | |
| Lizard Bearish | Bearish Day Trade Setup | -5.86% | |
| Calm After Storm | Range Contraction | -5.86% | |
| Doji - Bearish? | Reversal | -5.86% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/19/2020
- Sector: Healthcare
- Industry: Biotechnology
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. The company lead product comprises Vascepa, a prescription-only omega-3 fatty acid comprising icosapent ethyl as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It also engages in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.
Biopharmaceutical Organic Compounds Nutrition Cardiovascular Diseases Cholesterol Lipids Low Density Lipoprotein Hypertriglyceridemia Saturated Fat
Biopharmaceutical Organic Compounds Nutrition Cardiovascular Diseases Cholesterol Lipids Low Density Lipoprotein Hypertriglyceridemia Saturated Fat
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.12 |
| 52 Week Low | 3.95 |
| Average Volume | 5,956,152 |
| 200-Day Moving Average | 12.98 |
| 50-Day Moving Average | 6.79 |
| 20-Day Moving Average | 6.71 |
| 10-Day Moving Average | 6.78 |
| Average True Range | 0.36 |
| ADX | 20.83 |
| +DI | 23.69 |
| -DI | 14.60 |
| Chandelier Exit (Long, 3 ATRs ) | 6.29 |
| Chandelier Exit (Short, 3 ATRs ) | 7.38 |
| Upper Bollinger Band | 7.10 |
| Lower Bollinger Band | 6.33 |
| Percent B (%b) | 0.34 |
| BandWidth | 11.55 |
| MACD Line | 0.02 |
| MACD Signal Line | -0.02 |
| MACD Histogram | 0.0339 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.28 | ||||
| Resistance 3 (R3) | 7.35 | 7.20 | 7.17 | ||
| Resistance 2 (R2) | 7.20 | 7.02 | 7.16 | 7.13 | |
| Resistance 1 (R1) | 6.89 | 6.91 | 6.82 | 6.82 | 7.09 |
| Pivot Point | 6.74 | 6.74 | 6.70 | 6.70 | 6.74 |
| Support 1 (S1) | 6.43 | 6.56 | 6.36 | 6.36 | 6.09 |
| Support 2 (S2) | 6.28 | 6.45 | 6.24 | 6.05 | |
| Support 3 (S3) | 5.97 | 6.28 | 6.02 | ||
| Support 4 (S4) | 5.90 |
